In a clinical trial assessing the anti-inflammatory effects on cardiovascular disease of a novel inhibitor of IL-1β (Canakinumab, ACZ885, Ilaris), the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), the authors also documented an impressive decrease in NSCLC incidence and mortality, an outcome recognizing the potential of IL-1β inhibition in NSCLC [54,55]. The gene discussed is IL1B; the disease is cardiovascular disorder.